NEW YORK – Day One Biopharmaceuticals said on Tuesday it has inked an exclusive global licensing agreement with Darmstadt, Germany-headquartered Merck KGaA to develop and commercialize Merck's investigational MEK inhibitors, pimasertib and MSC2015103B.
Although the companies didn't disclose specific financial details of the deal, Day One paid Merck an upfront fee to license the drugs. Merck will also receive payments when certain regulatory, market approval, and sales milestones are met, and will receive royalties on future net sales of pimasertib and MSC2015103B.